首页> 外文期刊>Talanta: The International Journal of Pure and Applied Analytical Chemistry >An ssDNA aptamer selected by Cell-SELEX for the targeted imaging of poorly differentiated gastric cancer tissue
【24h】

An ssDNA aptamer selected by Cell-SELEX for the targeted imaging of poorly differentiated gastric cancer tissue

机译:由细胞 - 选择性选择的SSDNA适体,用于靶向胃癌组织差异差异差异的胃癌组织

获取原文
获取原文并翻译 | 示例
           

摘要

Gastric cancer (GC) is associated with high morbidity and mortality rates worldwide. Poorly differentiated GC predicts a poor prognosis and is related to patients' response to chemotherapy and targeted therapy. Therefore, it is very important to accurately evaluate the tumour differentiation status for the treatment of poorly differentiated GC. To develop a molecular probe to analyse poorly differentiated GC, we selected aptamers against poorly differentiated GC by subtractive Cell-SELEX using the poorly differentiated GC cell line BGC-823 as the target and the moderately differentiated GC cell line SGC-7901 as the negative control. After 15 rounds of selection, aptamer PDGC21 exhibited the highest affinity, and the K-d value of the truncated aptamer PDGC21-T was 35.2 +/- 1.1 nM. Aptamer PDGC21-T not only specifically bound to the target cells but also bound to other poorly differentiated GC cells. When combined with fluorescent nanoparticle quantum dots (QDs), the PDGC21T-QD probe could distinguish poorly differentiated GC cells in mixed culture cells and clinical specimens. Furthermore, in a tissue microarray containing 15 cases from patients, there was a higher positive rate in GC tissues compared with adjacent normal tissues; in poorly differentiated tissues, in particular, the fluorescence signal was significantly higher than that in well/moderately differentiated tissues. Therefore, aptamer PDGC21-T holds great potential for use as a molecular imaging probe for the detection of poorly differentiated GC, which is of great significance for diagnosis and treatment.
机译:胃癌(GC)与全世界的高发病率和死亡率相关。差异化的GC不良预测预后差,与患者对化疗和靶向治疗的反应有关。因此,准确评价肿瘤分化状态非常重要,以治疗差异不良的GC。为了开发分子探针以分析差异化的GC差,我们通过减少细胞 - SELEX选择适体对抗差异化的GC,使用差异分化的GC细胞系BGC-823作为靶标,并且中等分化的GC细胞系SGC-7901作为负控制。在15轮选择后,Aptamer PDGC21表现出最高亲和力,截短的适体PDGC21-T的K-D值为35.2 +/- 1.1nm。适体PDGC21-T不仅特别地与靶细胞结合,还与其他不良的GC细胞结合。当与荧光纳米颗粒量子点(QDS)结合时,PDGC21T-QD探针可以区分混合培养细胞和临床标本中的差异差异化的GC细胞。此外,在含有15例患者的组织微阵列中,与相邻的正常组织相比,GC组织中的阳性率较高;特别地,在分化不良的组织中,特别是荧光信号显着高于井/中等分化的组织中的荧光信号。因此,适体PDGC21-T具有巨大用作用于检测差异不良GC的分子成像探针,这对于诊断和治疗具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号